Effect of Nandrolone Decanoate on serum lipoprotein (a) and its isoforms in hemodialysis patients

Lipids in Health and Disease
Amir GhorbanihaghjoNadereh Rashtchizadeh

Abstract

Malnutrition, anemia and increased atherosclerosis are the main causes of mortality in hemodialysis patients. Therapies designed to improve the disorders might therefore be expected to improve outcome. The effects of Nandrolone Decanoate (ND), in 64 stable hemodialysis patients, were studied with respect to the following parameters: nutritional status, hematological indexes, lipid profiles including serum levels of lipoprotein(a) [Lp(a)] in terms of differences in apolipoprotein(a) [apo(a)]. The patients were treated with ND at dose of 100 mg/I.M./week for 4 months. After 2 and 4 months of treatment the elevations in the serum levels of albumin (p < 0.0001), creatinine (p < 0.009), hemoglobin (p < 0.03), hematocrit (p < 0.03), cholesterol (p = 0.007) and triglyceride (p < 0.04) were noticed. Marked decrease in the concentration of high-density lipoprotein cholesterol (p = 0.007) and Lp(a) (p < 0.0001) were also found. These effects after 2 months of treatment withdrawal were relatively constant. By dividing patients according to the baseline Lp(a) levels and molecular weight of apo(a) isoform, it was noticed that the decrease in serum Lp(a) was significant in patients with high Lp(a) (> 30 mg/dl) than those of with low Lp(a) (<...Continue Reading

References

Nov 17, 1989·Science·G Utermann
May 1, 1995·Clinical Cardiology·S HaffnerP LaBelle
Jan 1, 1994·Chemistry and Physics of Lipids·M I KambohW S Pollitzer
Jun 1, 1993·Journal of Clinical Pharmacology·D B HunninghakeM J Mellies
Feb 1, 1996·Current Opinion in Lipidology·P L Zock, R P Mensink
Nov 15, 1996·Atherosclerosis·D L Rainwater
Dec 16, 1998·Clinica Chimica Acta; International Journal of Clinical Chemistry·S MartínJ Rubiés-Prat
Apr 20, 1999·JAMA : the Journal of the American Medical Association·K L JohansenM Schambelan
Jun 3, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·H J MilionisK C Siamopoulos
Mar 31, 2000·Seminars in Dialysis·C A Johnson
Aug 5, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Edmund CauzaKaram Kostner
Aug 26, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Darren S ParsonsEdwina A Brown
Oct 11, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Juan F Navarro
Dec 4, 2003·The New England Journal of Medicine·Angelo M Scanu
Jan 14, 2004·Kidney International·Florian KronenbergHans Dieplinger
Mar 27, 2004·Seminars in Dialysis·Christopher T Chan
Jul 14, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Sotirios TsimikasAlexandros D Tselepis

❮ Previous
Next ❯

Citations

Sep 25, 2015·Expert Opinion on Drug Safety·Seul Min Choi, Byung-Mu Lee
Sep 1, 2017·American Journal of Nephrology·Jerry YuConnie M Rhee
Nov 15, 2020·Medicina·Federico Giuseppe PatanèAngelo Montana

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis

Software Mentioned

SPSS

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.